Copyright © 2006 Elsevier Ltd All rights reserved.
Antibacterial peptides for therapeutic use: obstacles and realistic outlook
Available online 4 August 2006.
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Cationic antimicrobial peptides are produced by almost all species of life as a component of their immediate non-specific defense against infections. The assets of these peptides in clinical application include their potential for broad-spectrum activity, rapid bactericidal activity and low propensity for resistance development, whereas possible disadvantages include their high cost, limited stability (especially when composed of L-amino acids), and unknown toxicology and pharmacokinetics. Initial barriers to their success are being increasingly overcome with the development of stable, more cost-effective and potent broad-spectrum synthetic peptides. Thus, there is hope that they will spawn a new generation of antimicrobials with a broad range of topical and systemic applications against infections.






E-mail Article
Add to my Quick Links

Cited By in Scopus (27)





